Technical Analysis for VCNX - Vaccinex, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
3.64 | -1.62% | -0.06 |
VCNX closed down 1.62 percent on Friday, June 5, 2020, on approximately normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical VCNX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -1.62% | |
| Pocket Pivot | Bullish Swing Setup | -1.62% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Biotechnology Health Cancer Biology Immunology Antibodies Immune System Monoclonal Antibodies Antibody Multiple Sclerosis Non Small Cell Lung Cancer Serious Diseases Melanoma Autoimmune Disorders Neurodegenerative Diseases Treatment Of Non Small Cell Lung Cancer Osteosarcoma Tolerx Treatment Of Multiple Sclerosis Nsclc Seth Lederman
Biotechnology Health Cancer Biology Immunology Antibodies Immune System Monoclonal Antibodies Antibody Multiple Sclerosis Non Small Cell Lung Cancer Serious Diseases Melanoma Autoimmune Disorders Neurodegenerative Diseases Treatment Of Non Small Cell Lung Cancer Osteosarcoma Tolerx Treatment Of Multiple Sclerosis Nsclc Seth Lederman
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.23 |
| 52 Week Low | 3.3769 |
| Average Volume | 51,201 |
| 200-Day Moving Average | 5.13 |
| 50-Day Moving Average | 3.82 |
| 20-Day Moving Average | 3.79 |
| 10-Day Moving Average | 3.76 |
| Average True Range | 0.26 |
| ADX | 11.68 |
| +DI | 14.70 |
| -DI | 15.88 |
| Chandelier Exit (Long, 3 ATRs ) | 3.31 |
| Chandelier Exit (Short, 3 ATRs ) | 4.32 |
| Upper Bollinger Band | 3.97 |
| Lower Bollinger Band | 3.61 |
| Percent B (%b) | 0.08 |
| BandWidth | 9.41 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.06 | ||||
| Resistance 3 (R3) | 4.09 | 3.98 | 3.99 | ||
| Resistance 2 (R2) | 3.98 | 3.87 | 3.96 | 3.97 | |
| Resistance 1 (R1) | 3.81 | 3.80 | 3.75 | 3.78 | 3.94 |
| Pivot Point | 3.70 | 3.70 | 3.67 | 3.68 | 3.70 |
| Support 1 (S1) | 3.53 | 3.59 | 3.47 | 3.50 | 3.34 |
| Support 2 (S2) | 3.42 | 3.52 | 3.40 | 3.31 | |
| Support 3 (S3) | 3.25 | 3.42 | 3.29 | ||
| Support 4 (S4) | 3.22 |
